Research Study

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Principal Investigator 
Graham Wong

Overview

Body Locations and Systems 
Disorders and Conditions 
ClinicalTrials.gov# 
NCT02019264
Status 
Closed to Recruitment
Study Start/End 
Aug 1, 2014 to Dec 31, 2019
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Naomi Uchida, Study Coordinator
Phone 
604-875-4521
Email Address 
naomi.uchida@ubc.ca
Purpose of Study 

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with CV disease and/or multiple CV risk factors.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.